Four divisions will be women’s health, urology/gastroenterology, dermatology/established brands and business operations
Dublin-headquartered Actavis has restructured its US Specialty Brands business to maximise its newly strengthened position in key therapeutic areas following the acquisition of Warner Chilcott.
Under its new structure, Actavis’ US Specialty Brands business will be divided into four business units: Women’s Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations.
Herm Cukier will lead the Women’s Healthcare category; Charles Sabino heads the Urology and GI therapeutic category; while Thomas Griffin gains a promotion to lead the Business Operations team. The fourth manager for the Dermatology and Established Brands business will be announced in due course.
‘The significant increase in size and complexity of our US Specialty Brands business, following the acquisition of Warner Chilcott last year, demands that we have the right structure and exceptional leadership team in place to drive our continued commercial success in the future,’ said Fred Wilkinson, President of Actavis Speciality Brands.
‘We believe this business unit structure will provide the most effective way to manage our larger portfolio, provide deeper product and customer insights and deliver the necessary focus to drive continued growth in each therapeutic category within our US Specialty Brands business.’
We believe this business unit structure will provide the most effective way to manage our larger portfolio
Cukier joins Actavis from Bayer, where was most recently Vice President, Marketing and Commercial Operations for Women's Healthcare. Prior to this, he was President and CEO of Reverion Pharmaceuticals, a start-up biotech company, General Manager at Schering Plough and Chief Marketing Officer at Organon. Earlier in his career Cukier held positions of increasing commercial responsibility at Bristol Myers Squibb and Pfizer.
Sabino joins Actavis from Aptalis Pharma, where he was most recently Vice President, Marketing for the speciality pharmaceutical company focused on Gastroenterology and Cystic Fibrosis treatments. Before Aptalis, Sabino was Chief Operating Officer for Lipose, a medical device company, and as a Managing Director for Cline, Davis & Mann, the second-largest healthcare advertising agency in the US. He also held positions of increasing responsibility within Pfizer and Novartis.
The newly created US Business Operations group will be responsible for all shared commercial functions for the respective US therapeutic business units, including sales operations, sales training, marketing research, sales analytics and managed markets field teams.
Griffin has been with Actavis since 2011 as VP, Sales and Operations for the US Specialty Brands business. Before joining Actavis, he was VP, Sales for Bayer Diabetes Care from 2008 to 2010, and prior to that spent 19 years in the Pfizer sales organisation in positions of increasing responsibility, culminating in Senior VP Sales for the Urology-Respiratory therapeutic cluster.